サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1413138

次世代婦人科がん診断薬市場：構成要素、技術、適応症、エンドユーザー別-2024-2030年の世界予測

Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 181 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
次世代婦人科がん診断薬市場：構成要素、技術、適応症、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 181 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

次世代婦人科がん診断薬市場規模は2023年に21億3,000万米ドルと推計され、2024年には23億2,000万米ドルに達し、CAGR 10.49%で2030年には42億9,000万米ドルに達すると予測されます。

次世代婦人科がん診断薬の世界市場

主な市場の統計
基準年[2023］ 21億3,000万米ドル
予測年[2024］ 23億2,000万米ドル
予測年 [2030] 42億9,000万米ドル
CAGR（%） 10.49%
次世代婦人科がん診断薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは次世代婦人科がん診断薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、次世代婦人科がん診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-次世代婦人科がん診断薬市場の市場規模および予測は？

2-次世代婦人科がん診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-次世代婦人科がん診断薬市場における技術動向と規制の枠組みは？

4-次世代婦人科がん診断薬市場における主要ベンダーの市場シェアは？

5-次世代婦人科がん診断薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 次世代婦人科がんの発生率の増加
      • 病気の早期診断と治療への傾向
      • 新規マーカー・遺伝マーカーの活用
    • 抑制要因
      • 次世代婦人科がん診断に伴う高額なコスト
    • 機会
      • 遠隔医療と遠隔監視の新たなトレンド
      • 上映プログラムと医療ツーリズムの増加
    • 課題
      • 次世代婦人科がん診断検査の製造における複雑さ
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 次世代婦人科がん診断薬市場：コンポーネント別

  • 消耗品
  • 機器
  • ソフトウェア

第7章 次世代婦人科がん診断薬市場：技術別

  • 次世代シーケンス（NGS）
  • ポリメラーゼ連鎖反応（PCR）

第8章 次世代婦人科がん診断薬市場適応症別

  • 子宮頸がん
  • 卵巣がん
  • 子宮がん

第9章 次世代婦人科がん診断薬市場：エンドユーザー別

  • 学術調査機関
  • 診断研究所
  • 病院と外来センター

第10章 南北アメリカの次世代婦人科がん診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の次世代婦人科がん診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの次世代婦人科がん診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • ARUP Laboratories
    • Becton, Dickinson and Company
    • BGI Genomics Co., Ltd.
    • Bio-Rad Laboratories, Inc.
    • Centogene N.V.
    • Danaher Corporation
    • Epic Sciences Inc.
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • Fujifilm Holdings Corporation
    • Fulgent Genetics, Inc.
    • GE HealthCare Technologies, Inc.
    • Hologic, Inc.
    • Illumina, Inc.
    • Interpace Diagnostics, LLC
    • Janssen Pharmaceuticals, Inc.
    • Konica Minolta, Inc.
    • Koninklijke Philips N.V.
    • Lucence Diagnostics Pte Ltd
    • Medtronic plc
    • Merck KGaA
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • Novartis AG
    • QIAGEN N.V.
    • Siemens Healthineers AG
    • Thermo Fisher Scientific Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
  • FIGURE 8. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 12. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 6. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 10. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 17. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 46. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 104. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 189. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-5C6F41F5B008

[181 Pages Report] The Next-Generation Gynecological Cancer Diagnostics Market size was estimated at USD 2.13 billion in 2023 and expected to reach USD 2.32 billion in 2024, at a CAGR 10.49% to reach USD 4.29 billion by 2030.

Global Next-Generation Gynecological Cancer Diagnostics Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.13 billion
Estimated Year [2024] USD 2.32 billion
Forecast Year [2030] USD 4.29 billion
CAGR (%) 10.49%
Next-Generation Gynecological Cancer Diagnostics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Next-Generation Gynecological Cancer Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Next-Generation Gynecological Cancer Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Gynecological Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Becton, Dickinson and Company, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Fulgent Genetics, Inc., GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Interpace Diagnostics, LLC, Janssen Pharmaceuticals, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Lucence Diagnostics Pte Ltd, Medtronic plc, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Novartis AG, QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Gynecological Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Components
    • Consumables
    • Instruments
    • Software
  • Technology
    • Next-Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
  • Indication
    • Cervical Cancer
    • Ovarian Cancer
    • Uterine Cancer
  • End User
    • Academic & Research Institutes
    • Diagnostic Laboratories
    • Hospitals & Ambulatory Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Next-Generation Gynecological Cancer Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Next-Generation Gynecological Cancer Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Next-Generation Gynecological Cancer Diagnostics Market?

4. What is the market share of the leading vendors in the Next-Generation Gynecological Cancer Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Next-Generation Gynecological Cancer Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Next-Generation Gynecological Cancer Diagnostics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of next-generation gynecological cancer cases
      • 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
      • 5.1.1.3. Utilization of novel markers and genetic markers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with next generation gynecological cancer diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend of telemedicine and remote monitoring
      • 5.1.3.2. Growing number of screening programs and medical tourism
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of next generation gynecological cancer diagnostics tests
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Next-Generation Gynecological Cancer Diagnostics Market, by Components

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Instruments
  • 6.4. Software

7. Next-Generation Gynecological Cancer Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Next-Generation Sequencing (NGS)
  • 7.3. Polymerase Chain Reaction (PCR)

8. Next-Generation Gynecological Cancer Diagnostics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cervical Cancer
  • 8.3. Ovarian Cancer
  • 8.4. Uterine Cancer

9. Next-Generation Gynecological Cancer Diagnostics Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Ambulatory Centers

10. Americas Next-Generation Gynecological Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Agilent Technologies, Inc.
    • 14.1.3. ARUP Laboratories
    • 14.1.4. Becton, Dickinson and Company
    • 14.1.5. BGI Genomics Co., Ltd.
    • 14.1.6. Bio-Rad Laboratories, Inc.
    • 14.1.7. Centogene N.V.
    • 14.1.8. Danaher Corporation
    • 14.1.9. Epic Sciences Inc.
    • 14.1.10. Exact Sciences Corporation
    • 14.1.11. F. Hoffmann-La Roche Ltd.
    • 14.1.12. Fujifilm Holdings Corporation
    • 14.1.13. Fulgent Genetics, Inc.
    • 14.1.14. GE HealthCare Technologies, Inc.
    • 14.1.15. Hologic, Inc.
    • 14.1.16. Illumina, Inc.
    • 14.1.17. Interpace Diagnostics, LLC
    • 14.1.18. Janssen Pharmaceuticals, Inc.
    • 14.1.19. Konica Minolta, Inc.
    • 14.1.20. Koninklijke Philips N.V.
    • 14.1.21. Lucence Diagnostics Pte Ltd
    • 14.1.22. Medtronic plc
    • 14.1.23. Merck KGaA
    • 14.1.24. Myriad Genetics, Inc.
    • 14.1.25. Natera, Inc.
    • 14.1.26. Novartis AG
    • 14.1.27. QIAGEN N.V.
    • 14.1.28. Siemens Healthineers AG
    • 14.1.29. Thermo Fisher Scientific Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing